Parabilis Medicines, Inc. (PBLS)

Company

Parabilis Medicines, Inc. (PBLS)

StatusJun 10, 2026
BiotechnologyBiotechnology
Initial Public Offering / IPOInitial Public Offering / IPO

We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. 

Chart/Sentiment

Financials

Parabilis Medicines, Inc. (PBLS)

Annual revenue is currently unavailable. More figures are available with Pro.

Scroll to Top